After Drop in Elective Surgeries, Medtech M&A Poised for a Rebound

1 Pages

Medtech deal activity slowed sharply as Covid‑19 caused elective surgeries in the US to drop by nearly 90 percent at the height of the pandemic, dragging down M&A across the sector. However, a rebound is expected as conditions stabilize. Diagnostics and testing companies, strengthened by recent cash inflows, are likely to pursue acquisitions to diversify into new growth areas. At the same time, companies with strong balance sheets are expected to seek acquisitions, including distressed assets, to expand capabilities and emerge as category leaders. These two forces could significantly boost medtech M&A activity as the sector recovers.

Join for free to read

After Drop in Elective Surgeries, Medtech M&A Poised for a Rebound

After Drop in Elective Surgeries, Medtech M&A Poised for a Rebound

You Might Also Like

More from Bain & Company

Infographic

After Drop in Elective Surgeries, Medtech M&A Poised for a Rebound

After Drop in Elective Surgeries, Medtech M&A Poised for a Rebound

You Might Also Like

More from Bain & Company